Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMRX NASDAQ:PALI NASDAQ:RANI NASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMRXImmuneering$4.31+0.4%$4.81$2.90▼$10.08$278.21M0.411.50 million shs1,160 shsPALIPalisade Bio$1.93+0.8%$1.92$0.53▼$2.86$334.14M1.54.02 million shs6,127 shsRANIRani Therapeutics$0.67-2.2%$0.83$0.42▼$3.87$83.12M0.781.01 million shs979 shsSNDLSNDL$1.29+0.4%$1.40$1.26▼$2.89$329.99M0.921.87 million shs4,342 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMRXImmuneering-7.54%-16.86%-2.72%-22.70%+3.87%PALIPalisade Bio-3.05%+1.06%+2.14%-31.79%+154.67%RANIRani Therapeutics-1.58%+8.49%-12.28%-27.59%+65.13%SNDLSNDL0.00%-2.29%-9.86%-15.23%-16.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMRXImmuneering$4.31+0.4%$4.81$2.90▼$10.08$278.21M0.411.50 million shs1,160 shsPALIPalisade Bio$1.93+0.8%$1.92$0.53▼$2.86$334.14M1.54.02 million shs6,127 shsRANIRani Therapeutics$0.67-2.2%$0.83$0.42▼$3.87$83.12M0.781.01 million shs979 shsSNDLSNDL$1.29+0.4%$1.40$1.26▼$2.89$329.99M0.921.87 million shs4,342 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMRXImmuneering-7.54%-16.86%-2.72%-22.70%+3.87%PALIPalisade Bio-3.05%+1.06%+2.14%-31.79%+154.67%RANIRani Therapeutics-1.58%+8.49%-12.28%-27.59%+65.13%SNDLSNDL0.00%-2.29%-9.86%-15.23%-16.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMRXImmuneering 2.86Moderate Buy$17.57307.78% UpsidePALIPalisade Bio 3.00Buy$8.83358.87% UpsideRANIRani Therapeutics 2.60Moderate Buy$8.751,204.02% UpsideSNDLSNDL 2.00Hold$5.00289.11% UpsideCurrent Analyst Ratings BreakdownLatest RANI, PALI, SNDL, and IMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026IMRXImmuneering Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $18.007/17/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/14/2026PALIPalisade Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.007/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.007/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.006/30/2026PALIPalisade Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$7.006/30/2026PALIPalisade Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.006/29/2026PALIPalisade Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/25/2026PALIPalisade Bio LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2026IMRXImmuneering Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMRXImmuneeringN/AN/AN/AN/A$3.38 per shareN/APALIPalisade Bio$250K1,336.57N/AN/A$0.87 per share2.21RANIRani Therapeutics$1.63M51.00N/AN/A$0.34 per share1.97SNDLSNDL$677.32M0.49$0.11 per share11.37$3.06 per share0.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMRXImmuneering-$56.03M-$1.17N/AN/AN/AN/A-31.93%-29.92%8/12/2026 (Estimated)PALIPalisade Bio-$16.78M-$1.01N/AN/AN/AN/A-36.79%-34.34%8/10/2026 (Estimated)RANIRani Therapeutics-$29.67M-$0.41N/AN/AN/AN/A-206.46%-83.95%8/6/2026 (Estimated)SNDLSNDL-$11.29M-$0.03N/A32.13N/A-1.19%-1.02%-0.85%7/28/2026 (Estimated)Latest RANI, PALI, SNDL, and IMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026IMRXImmuneering-$0.26N/AN/AN/AN/AN/A8/10/2026Q2 2026PALIPalisade Bio-$0.05N/AN/AN/AN/AN/A8/6/2026Q2 2026RANIRani Therapeutics-$0.05N/AN/AN/A$0.93 millionN/A7/28/2026Q2 2026SNDLSNDL-$0.01N/AN/AN/A$166.26 millionN/A5/15/2026Q1 2026IMRXImmuneering-$0.30-$0.21+$0.09-$0.21N/AN/A5/15/2026Q1 2026RANIRani Therapeutics-$0.06-$0.04+$0.02-$0.04$1.13 million$1.71 million5/12/2026Q1 2026PALIPalisade Bio-$0.04-$0.05-$0.01-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMRXImmuneeringN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMRXImmuneeringN/A32.4532.45PALIPalisade BioN/A23.7123.71RANIRani TherapeuticsN/A3.403.40SNDLSNDL0.124.843.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMRXImmuneering67.65%PALIPalisade Bio11.79%RANIRani Therapeutics30.19%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipIMRXImmuneering22.90%PALIPalisade Bio0.07%RANIRani Therapeutics26.73%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMRXImmuneering6064.70 million49.88 millionNot OptionablePALIPalisade Bio10173.58 million173.46 millionNot OptionableRANIRani Therapeutics110123.88 million90.77 millionOptionableSNDLSNDL2,751257.40 millionN/AOptionableRANI, PALI, SNDL, and IMRX HeadlinesRecent News About These CompaniesSNDL (SNDL) Expected to Post Quarterly Earnings on Tuesday3 hours ago | marketbeat.comSNDL (NASDAQ:SNDL) Stock Price Down 0.8% - What's Next?July 17, 2026 | marketbeat.comWhat Sets SNDL (NASDAQ:SNDL) Apart Among Cannabis Stocks?July 17, 2026 | kalkinemedia.comKSNDL to Report Second Quarter 2026 Financial Results on July 28, 2026July 15, 2026 | finance.yahoo.comSNDL to Report Second Quarter 2026 Financial Results on July 28, 2026July 15, 2026 | financialpost.comFSNDL Inc. to Report Second Quarter 2026 Financial Results on July 28, 2026July 15, 2026 | quiverquant.comQSNDL to Report Second Quarter 2026 Financial Results on July 28, 2026July 15, 2026 | globenewswire.comIs SNDL Inc. (NASDAQ:SNDL) Still A Penny Stock To Watch?July 13, 2026 | kalkinemedia.comKRegulator ordered cannabis producer SNDL to sell Ontario stores or risk having licences revoked, letter showsJune 12, 2026 | theglobeandmail.comCORRECTING and REPLACING Sundial Media & Technology Group Names Cedric J. Rogers Chief Product & Platform OfficerJune 2, 2026 | businesswire.comSundial Media & Technology Group Formally Establishes Chief Product & Platform Officer Role, Names Cedric J. Rogers to Lead Creator Ecosystem StrategyJune 2, 2026 | businesswire.comAfter Rough Q1, SNDL Inc (SNDL) Sees Cannabis Market ImprovingMay 31, 2026 | finance.yahoo.comSNDL Drops Ontario Store Acquisition, Shifts Capital to Share BuybacksMay 30, 2026 | theglobeandmail.com1CM Provides Update on Arrangement Agreement with SNDLMay 27, 2026 | finance.yahoo.comSNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis StoresMay 27, 2026 | finance.yahoo.com1CM Provides Update on Arrangement Agreement with SNDLMay 27, 2026 | newsfilecorp.comNSNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis StoresMay 27, 2026 | financialpost.comFSNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis StoresMay 27, 2026 | globenewswire.comMay 2026's Promising Penny Stocks To ConsiderMay 25, 2026 | finance.yahoo.comTop Canadian Marijuana Stock Choices For Better Investing In 2026May 22, 2026 | marijuanastocks.comMAlliance Global Partners Keeps Their Buy Rating on SNDL (SNDL)May 6, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesEnergy Fuels Just Made a Bold Bet on Rare Earth MagnetsBy Jeffrey Neal Johnson | June 25, 2026Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally HereBy Jeffrey Neal Johnson | June 26, 20263 ETFs Pairing Market-Beating Returns With High Dividend YieldsBy Nathan Reiff | June 27, 2026Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand RisesBy Nathan Reiff | July 19, 2026Fission for Profits: Unlocking America’s Uranium VaultBy Jeffrey Neal Johnson | July 14, 2026RANI, PALI, SNDL, and IMRX Company DescriptionsImmuneering NASDAQ:IMRX$4.31 +0.02 (+0.44%) As of 09:31 AM Eastern This is a fair market value price provided by Massive. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Palisade Bio NASDAQ:PALI$1.92 +0.02 (+0.79%) As of 09:32 AM Eastern This is a fair market value price provided by Massive. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.Rani Therapeutics NASDAQ:RANI$0.67 -0.02 (-2.23%) As of 09:31 AM Eastern This is a fair market value price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.SNDL NASDAQ:SNDL$1.28 +0.01 (+0.39%) As of 09:31 AM Eastern This is a fair market value price provided by Massive. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? IBM Just Had Its Worst Day Ever—What Earnings Must Prove AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Oracle Is One Step From Junk—Can It Afford the AI Boom? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
